Practice-Changing Trial in Metastatic Papillary RCC

(MedPage Today) -- Cabozantinib (Cabometyx) came out on top as upfront therapy in metastatic papillary renal cell carcinoma (RCC) in a randomized phase II study.
Treatment with the multikinase inhibitor yielded a median progression-free survival...